For
the quarter ending March 2024, consolidated Net sales (including other operating income) of Dr Lal Pathlabs has increased 11.08% to Rs 545.4 crore compared to quarter ended March 2023. Operating profit margin has jumped from 23.54% to 26.53%, leading to 25.17% rise in operating profit to Rs 144.70 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 21.57% to 19.97%. Employee cost increased from 18.84% to 19.33%. Other expenses fell from 36.05% to 34.18%. Selling and administration expenses fell from 14.01% to 13.86%. Other income rose 29.58% to Rs 18.4 crore. PBIDT rose 25.65% to Rs 163.1 crore. Provision for interest fell 26.67% to Rs 6.6 crore. Loan funds declined from Rs 419.50 crore as of 31 March 2023 to Rs 246.90 crore as of 31 March 2024. Inventories rose to Rs 37.30 crore as of 31 March 2024 from Rs 33.80 crore as of 31 March 2023. Sundry debtors were higher at Rs 77.40 crore as of 31 March 2024 compared to Rs 70.80 crore as of 31 March 2023. Cash and bank balance rose to Rs 830.30 crore as of 31 March 2024 from Rs 665.40 crore as of 31 March 2023. Investments declined from Rs 149.90 crore as of 31 March 2023 to Rs 113.80 crore as of 31 March 2024.
PBDT rose 29.55% to Rs 156.5 crore. Provision for depreciation fell 2.66% to Rs 36.6 crore. Fixed assets declined from Rs 762.20 crore as of 31 March 2023 to Rs 685.00 crore as of 31 March 2024. Intangible assets increased from Rs 547.80 crore to Rs 548.20 crore.
Profit before tax grew 44.11% to Rs 119.90 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 34.1 crore, compared to Rs 26.3 crore. Effective tax rate was 28.44% compared to 31.61%.
Minority interest increased 550% to Rs 1.30 crore. Net profit attributable to owners of the company increased 49.03% to Rs 84.50 crore. Equity capital increased from Rs 83.40 crore as of 31 March 2023 to Rs 83.50 crore as of 31 March 2024. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 54.60% as of 31 March 2024 ,compared to 55.03% as of 31 March 2023 .
Full year results analysis.
Net sales (including other operating income) of Dr Lal Pathlabs has increased 10.40% to Rs 2226.6 crore. Operating profit margin has jumped from 24.29% to 27.36%, leading to 24.37% rise in operating profit to Rs 609.30 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 22.17% to 20.27%. Employee cost increased from 18.67% to 19.06%. Other expenses fell from 34.87% to 33.30%. Selling and administration expenses rose from 13.98% to 14.06%. Other income rose 65.95% to Rs 69.2 crore. PBIDT rose 27.63% to Rs 678.5 crore. Provision for interest fell 21.60% to Rs 29.4 crore. Loan funds declined from Rs 419.50 crore as of 31 March 2023 to Rs 246.90 crore as of 31 March 2024. Inventories rose to Rs 37.30 crore as of 31 March 2024 from Rs 33.80 crore as of 31 March 2023. Sundry debtors were higher at Rs 77.40 crore as of 31 March 2024 compared to Rs 70.80 crore as of 31 March 2023. Cash and bank balance rose to Rs 830.30 crore as of 31 March 2024 from Rs 665.40 crore as of 31 March 2023. Investments declined from Rs 149.90 crore as of 31 March 2023 to Rs 113.80 crore as of 31 March 2024.
PBDT rose 31.37% to Rs 649.1 crore. Provision for depreciation fell 4.39% to Rs 143.6 crore. Fixed assets declined from Rs 762.20 crore as of 31 March 2023 to Rs 685.00 crore as of 31 March 2024. Intangible assets increased from Rs 547.80 crore to Rs 548.20 crore.
Profit before tax grew 46.99% to Rs 505.50 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 143.2 crore, compared to Rs 102.8 crore. Effective tax rate was 28.33% compared to 29.89%.
Minority interest increased 109.09% to Rs 4.60 crore. Net profit attributable to owners of the company increased 49.73% to Rs 357.70 crore.
Equity capital increased from Rs 83.40 crore as of 31 March 2023 to Rs 83.50 crore as of 31 March 2024. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 54.60% as of 31 March 2024 ,compared to 55.03% as of 31 March 2023 .
Cash flow from operating activities increased to Rs 535.40 crore for year ended March 2024 from Rs 456.00 crore for year ended March 2023. Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 57.50 crore, compared to Rs 44.60 crore during the year ended March 2023.
Other Highlights
The board recommendation of final dividend
of Rs 6 per equity share on a face value of Rs 10 each for the financial year
ended March 31, 2024. The record date for the purpose of payment of final
dividend shall be June 10, 2024.